From tomorrow (July 1st) the UK childhood vaccination schedule is being updated.
Key changes include the removal of the Hib/MenC (Menitorix) vaccine at 12 months, adjustments to the timing of MenB and PCV (pneumococcal) vaccines, and the introduction of a new 18-month appointment for a fourth dose of the 6-in-1 vaccine.
Here’s a more detailed breakdown:
Phase 1
Changes to the one-year appointment:
- Hib/MenC (Menitorix):
The combined Hib/MenC vaccine, given at the one-year appointment, is being discontinued.
- MenB and PCV:
The second dose of MenB vaccine will be moved from 16 weeks to 12 weeks, while the first dose of PCV vaccine will move from 12 weeks to 16 weeks.
- Selective Neonatal Hepatitis B programme:
The monovalent hepatitis B vaccine dose at one year will be discontinued for children in this program.
Phase 2
Introduction of an 18-month appointment from January 1st 2026:
- A new 18-month appointment will be introduced for a fourth dose of the 6-in-1 vaccine (DTaP/IPV/Hib/HepB).
- This fourth dose will replace the Hib component of the previously given Hib/MenC vaccine.
- The second dose of MMR vaccine may be moved from 3 years 4 months to 18 months at this appointment.
Rationale for the changes:
- The Hib/MenC vaccine is being discontinued because the sole brand, Menitorix, is no longer produced and stocks are being depleted.
- Adjusting the timing of the MenB and PCV vaccines is intended to provide better protection against MenB during the period when most cases occur (1-3 months).
- The fourth 6-in-1 dose at 18 months ensures continued strong immunity to diphtheria, tetanus, pertussis, polio, hepatitis B, and Hib.
- Moving the second MMR dose to 18 months may improve uptake and reduce measles outbreaks.
Parents/carers who have questions about the changes can speak to their health visitor and should continue to attend their vaccination appointment as scheduled.
